Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Donegal Group Class A
DGICA
$696M
| $5.95M | 0.01% |
374,000
+55,900
| +18% | +$912K |
|
|
CALY
1602
Callaway Golf Company
CALY
$2.94B
| $5.94M | 0.01% |
464,600
+250,300
| +117% | +$3.07M |
|
1603
Roper Technologies
ROP
$39.5B
| $5.93M | 0.01% |
25,600
-344,200
| -93% | -$76.2M |
|
|
HBP
1604
DELISTED
Huttig Building Products, Inc.
HBP
| $5.92M | 0.01% |
844,700
+128,223
| +18% | +$942K |
|
|
WFBI
1605
DELISTED
WashingtonFirst Bankshares Inc
WFBI
| $5.91M | 0.01% |
171,035
+71,800
| +72% | +$2.22M |
|
1606
Simulations Plus
SLP
$371M
| $5.91M | 0.01% |
478,147
-36,853
| -7% | -$438K |
|
1607
CEVA Inc
CEVA
$937M
| $5.9M | 0.01% |
129,800
-35,200
| -21% | -$1.45M |
|
1608
TechTarget
TTGT
$278M
| $5.87M | 0.01% |
566,394
-11,706
| -2% | -$110K |
|
|
KCG
1609
DELISTED
KCG Holdings, Inc.
KCG
| $5.84M | 0.01% |
293,071
+192,871
| +192% | +$3.74M |
|
1610
RPM International
RPM
$14.5B
| $5.84M | 0.01% |
+107,059
| New | +$5.73M |
|
|
TFCF
1611
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $5.84M | 0.01% |
209,392
| – | – |
|
|
WSTC
1612
DELISTED
West Corporation
WSTC
| $5.83M | 0.01% |
250,100
+137,900
| +123% | +$3.28M |
|
|
IPXL
1613
DELISTED
Impax Laboratories, Inc.
IPXL
| $5.83M | 0.01% |
362,200
-181,900
| -33% | -$2.69M |
|
1614
Arbor Realty Trust
ABR
$950M
| $5.82M | 0.01% |
697,500
-16,037
| -2% | -$135K |
|
1615
Columbia Sportswear
COLM
$2.94B
| $5.8M | 0.01% |
99,902
-176,500
| -64% | -$9.98M |
|
|
DERM
1616
DELISTED
Dermira, Inc.
DERM
| $5.78M | 0.01% |
198,300
+168,300
| +561% | +$5.12M |
|
1617
Gaia
GAIA
$37.1M
| $5.78M | 0.01% |
515,600
+55,200
| +12% | +$609K |
|
|
XCRA
1618
DELISTED
Xcerra Corporation
XCRA
| $5.77M | 0.01% |
590,500
-492,399
| -45% | -$4.78M |
|
1619
Grupo Aval
AVAL
$6.29B
| $5.76M | 0.01% |
695,776
+7,076
| +1% | +$58.3K |
|
1620
Luxfer Holdings
LXFR
$457M
| $5.74M | 0.01% |
448,700
+36,200
| +9% | +$439K |
|
1621
U-Haul Holding Co
UHAL
$14.4B
| $5.74M | 0.01% |
156,660
-128,000
| -45% | -$4.64M |
|
1622
IES Holdings
IESC
$15.1B
| $5.73M | 0.01% |
315,632
-127,000
| -29% | -$2.2M |
|
1623
AXT Inc
AXTI
$5.34B
| $5.73M | 0.01% |
902,100
+66,240
| +8% | +$433K |
|
1624
Manchester United
MANU
$4.17B
| $5.71M | 0.01% |
351,500
-39,200
| -10% | -$649K |
|
1625
QuinStreet
QNST
$1.18B
| $5.69M | 0.01% |
1,364,300
+26,200
| +2% | +$105K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.